FDA approval of Akynzeo®

The U.S. Food & Drug Administration approves Helsinn's drug Akynzeo®

European Commission (EC) approved Akynzeo® in the European Union

European Commission (EC)  approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin‑based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union. 

Prev Next

November 30, 2015

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announ...


November 23, 2015

In the presence of Mr. Christian Vitta, Director of the Finance and Economic Department, Mr. ...


November 17, 2015

Helsinn Group announced today that the U.S. District Court for the District of New Jersey has...


November 13, 2015

Helsinn Group and Eisai Inc. announced today that the American Society of Clinical Oncology (...